Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance

Abstract Abatacept, an inhibitor of CD28 mediated T-cell activation, has been shown to be effective in controlling inflammation during rheumatoid arthritis (RA). However, its effects on immune regulatory B and T cells (Bregs and Tregs) has not been fully explored. Thirty-one RA patients treated with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maha Fahad Alenazy, Fatemeh Saheb Sharif-Askari, Mohammed A. Omair, Mohammad S. El-Wetidy, Maha A. Omair, Hussam Mitwalli, Saleh Al-Muhsen, Abeer Al-Masri, Qutayba Hamid, Rabih Halwani
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/947ebe4548714661b13f3501c3da0099
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:947ebe4548714661b13f3501c3da0099
record_format	dspace
spelling	oai:doaj.org-article:947ebe4548714661b13f3501c3da00992021-12-02T13:30:12ZAbatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance10.1038/s41598-021-83615-02045-2322https://doaj.org/article/947ebe4548714661b13f3501c3da00992021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83615-0https://doaj.org/toc/2045-2322Abstract Abatacept, an inhibitor of CD28 mediated T-cell activation, has been shown to be effective in controlling inflammation during rheumatoid arthritis (RA). However, its effects on immune regulatory B and T cells (Bregs and Tregs) has not been fully explored. Thirty-one RA patients treated with abatacept for ≥ 6 months along with 31 RA patients treated with other modalities as well as 30 healthy controls were recruited. Of these 62 RA patient, 49 (79%) were females with a mean age of 54 ± 12 years and disease duration of 10 ± 6 years. The blood levels of Tregs and Bregs and their production of immunosuppressive cytokines, were determined using FACS analysis and Luminex Multiplex assay. Treatment with abatacept significantly enhanced the blood level of IL-35+ IL-10+ Bregs (P = 0.0007). Their levels were higher in the blood of remitted patients (DAS28-CRP < 2.6) compared to the unremitted ones (P = 0.0173), 6 months following abatacept treatment initiation. Moreover, abatacept treatment significantly enhanced the blood levels of LAG3+ conventional and unconventional Tregs of RA patients. This increase in the blood levels of Bregs and Tregs was accompanied with an elevated serum level of IL-35 and IFN-β in abatacept-treated patients. Therefore, Abatacept efficiency to achieve remittance in RA could be attributed, in part, to its ability to enhance immune regulatory cells, especially IL-135+ IL-10+ Bregs.Maha Fahad AlenazyFatemeh Saheb Sharif-AskariMohammed A. OmairMohammad S. El-WetidyMaha A. OmairHussam MitwalliSaleh Al-MuhsenAbeer Al-MasriQutayba HamidRabih HalwaniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maha Fahad Alenazy Fatemeh Saheb Sharif-Askari Mohammed A. Omair Mohammad S. El-Wetidy Maha A. Omair Hussam Mitwalli Saleh Al-Muhsen Abeer Al-Masri Qutayba Hamid Rabih Halwani Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
description	Abstract Abatacept, an inhibitor of CD28 mediated T-cell activation, has been shown to be effective in controlling inflammation during rheumatoid arthritis (RA). However, its effects on immune regulatory B and T cells (Bregs and Tregs) has not been fully explored. Thirty-one RA patients treated with abatacept for ≥ 6 months along with 31 RA patients treated with other modalities as well as 30 healthy controls were recruited. Of these 62 RA patient, 49 (79%) were females with a mean age of 54 ± 12 years and disease duration of 10 ± 6 years. The blood levels of Tregs and Bregs and their production of immunosuppressive cytokines, were determined using FACS analysis and Luminex Multiplex assay. Treatment with abatacept significantly enhanced the blood level of IL-35+ IL-10+ Bregs (P = 0.0007). Their levels were higher in the blood of remitted patients (DAS28-CRP < 2.6) compared to the unremitted ones (P = 0.0173), 6 months following abatacept treatment initiation. Moreover, abatacept treatment significantly enhanced the blood levels of LAG3+ conventional and unconventional Tregs of RA patients. This increase in the blood levels of Bregs and Tregs was accompanied with an elevated serum level of IL-35 and IFN-β in abatacept-treated patients. Therefore, Abatacept efficiency to achieve remittance in RA could be attributed, in part, to its ability to enhance immune regulatory cells, especially IL-135+ IL-10+ Bregs.
format	article
author	Maha Fahad Alenazy Fatemeh Saheb Sharif-Askari Mohammed A. Omair Mohammad S. El-Wetidy Maha A. Omair Hussam Mitwalli Saleh Al-Muhsen Abeer Al-Masri Qutayba Hamid Rabih Halwani
author_facet	Maha Fahad Alenazy Fatemeh Saheb Sharif-Askari Mohammed A. Omair Mohammad S. El-Wetidy Maha A. Omair Hussam Mitwalli Saleh Al-Muhsen Abeer Al-Masri Qutayba Hamid Rabih Halwani
author_sort	Maha Fahad Alenazy
title	Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
title_short	Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
title_full	Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
title_fullStr	Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
title_full_unstemmed	Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance
title_sort	abatacept enhances blood regulatory b cells of rheumatoid arthritis patients to a level that associates with disease remittance
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/947ebe4548714661b13f3501c3da0099
work_keys_str_mv	AT mahafahadalenazy abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT fatemehsahebsharifaskari abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT mohammedaomair abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT mohammadselwetidy abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT mahaaomair abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT hussammitwalli abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT salehalmuhsen abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT abeeralmasri abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT qutaybahamid abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance AT rabihhalwani abataceptenhancesbloodregulatorybcellsofrheumatoidarthritispatientstoalevelthatassociateswithdiseaseremittance
_version_	1718392929259618304

Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance

Ejemplares similares